解封海洋天然产品研究的政策发展:科学家指南给DSI和BBNJ
Federica Casolari1, Amelia Westmoreland2,3, Thomas Vanagt2
1Department of Chemistry, Marine Biodiscovery Centre, University of Aberdeen, Aberdeen AB24 3UE, UK. m.jaspars@abdn.ac.uk.
Natural product reports
|April 17, 2025
概括
在国家管辖范围之外,数字序列信息 (DSI) 和海洋生物多样性的新政策对遗传资源研究产生了影响. 本指南有助于自然产品科学家驾这些不断变化的获取和利益共享 (ABS) 规定.
科学领域:
- 海洋自然产品科学 海洋自然产品科学
- 生物勘探是指生物勘探.
- 遗传资源研究 遗传资源研究
背景情况:
- "名古屋议定书" (2014年生效) 规定了对遗传资源的获取和利益共享 (ABS) 规定.
- 最近的政策发展,包括数字序列信息 (DSI) 和国家管辖范围之外的生物多样性 (BBNJ) 协议,带来了新的合规挑战.
- 对政策变化向研究人员进行有效的沟通仍然是一个关键的差距.
研究的目的:
- 为了简要概述最近影响自然产品研究人员的政策发展.
- 引导科学家协调他们的研究与不断变化的国际和国家ABS立法.
- 解决政策更新和研究人员可访问性之间的沟通差距.
主要方法:
- 审查与遗传资源有关的国际协议和政策文件.
- 分析了名古屋议定书,DSI法规和BBNJ协议的影响.
- 综合信息,为一个以研究人员为中心的指南.
主要成果:
- 名古屋议定书,DSI法规和BBNJ协议显著改变了获取和利用遗传资源的格局.
- 海洋天然产品科学家面临着关于国际水域数据共享和研究的新义务.
- 对于这些政策转变,人们显然需要可访问的沟通道.
结论:
- 自然产品研究人员必须适应来自DSI和BBNJ法规的新ABS合规要求.
- 弥合政策制定者和科学家之间的沟通差距对于持续的研究和资源利用至关重要.
- 积极参与这些不断变化的政策确保了伦理和有效的科学进步.
更多相关视频
07:59A Customizable Approach for the Enzymatic Production and Purification of Diterpenoid Natural Products
Published on: October 4, 2019
9.7K
16:03A Fish-feeding Laboratory Bioassay to Assess the Antipredatory Activity of Secondary Metabolites from the Tissues of Marine Organisms
Published on: January 11, 2015
9.4K
相关概念视频
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:27Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...